Introduction
The clustered Hox family of homeobox genes (class I homeobox genes) is an evolutionarily highly conserved set of genes that encode DNA-binding transcription factors that were first identified as key regulators of positional identity along the anterior-posterior body axis of animal embryos (Krumlauf, 1994) . In mammals, there are 39 Hox genes organized into four genomic clusters (A-D) located on four different chromosomes and, based on homeobox sequence similarity, consist of 13 paralogous groups, with no cluster containing a full set ( Figure 1 ). Hox genes exhibit a high degree of homology to the clustered homeotic genes (HOM-C) of Drosophila melanogaster, which are located in two gene clusters, the Antennapedia (Ant-C) and bithorax complexes (BX-C). Mammalian paralog groups 1-8 are more closely related to Ant-C genes, while paralog groups 9-13 are more closely related to the Abdominal-B (Abd-B) gene of the BX-C and are thus referred to as Abd-B class Hox genes (Figure 1 ). Non-clustered or non-Hox homeobox genes (class II homeobox genes) are more divergent, more numerous (approximately 160 in the human genome) (Tupler et al., 2001) and are dispersed throughout the genome. The highly conserved homeobox sequence motif, which encodes the homeodomain, a 60 amino-acid helix-turn-helix DNAbinding domain (Gehring et al., 1994) , is the common element defining these two broad classes of genes.
The enigmatic role of Hox genes in normal hematopoiesis
Gene expression analyses of both mouse and human bone marrow (BM) samples revealed that the majority of Hox genes of the A, B and C clusters are expressed in hematopoietic cells and, for the most part, are preferentially expressed in hematopoietic stem cell (HSC)-enriched subpopulations and in immature progenitor compartments and downregulated during differentiation and maturation (Giampaolo et al., 1994 (Giampaolo et al., , 1995 Moretti et al., 1994; Sauvageau et al., 1994; Kawagoe et al., 1999; Pineault et al., 2002) . These observations led to the hypotheses that Hox genes play key functions in early hematopoietic cells, including HSCs, and that dysregulated Hox expression may impact leukemic transformation.
Lessons from Hox overexpression and knockout models
The role of Hox genes in normal hematopoiesis has been extensively investigated through engineered overexpression from retroviral vectors and transgenic knockout and knock-in mouse models. While these studies have provided strong correlative evidence for the involvement of Hox genes in normal hematopoiesis, their precise role(s) and their mechanism(s) of action remain largely unclear.
Overexpression of Hox genes in HSCs from mouse BM, fetal liver and in human cord blood progenitors has provided a rich body of data showing potent effects of Hox on differentiation and proliferation. Details of the specific phenotypes have been extensively reviewed elsewhere and summarized in Figure 1 (Lawrence et al., 1996; Owens and Hawley, 2002; Grier et al., 2005) . For example, overexpression of Hoxa10, Hoxb3 and Hoxb6 in mouse BM cells had profound effects such as a block in the differentiation of B-and T cells, impaired erythropoiesis, and induction of myeloproliferative disorders and leukemia. One striking effect of Hox that has emerged from these studies is the potent impact of Hox on HSC self-renewal. This is graphically illustrated by initial findings relating to Hoxb4 and will be discussed in detail below.
The embryonic phenotypes of Hox knockout mouse models have revealed both unique and redundant or overlapping function of Hox genes and their sensitivity to gene dosage as observed by the phenotypic differences between single and compound Hox gene knockouts (Horan et al., 1995a, b; Zakany et al., 1996 Zakany et al., , 1997 Chen and Capecchi, 1997; Greer et al., 2000; Suemori and Noguchi, 2000) . Members of the Hox family also appear to play overlapping and diverse roles in hematopoiesis and challenge efforts to elucidate their specific and combined functions.
We previously documented that Hoxb4 is among the Hox genes expressed in primitive murine and human hematopoietic cells (Sauvageau et al., 1994; Pineault et al., 2002) and demonstrated that enforced overexpression or direct protein delivery of Hoxb4 is sufficient to stimulate marked HSC expansion in vivo and ex vivo without promoting leukemia (Sauvageau et al., 1995; Antonchuk et al., 2001 Antonchuk et al., , 2002 Amsellem et al., 2003) . These potent effects of Hoxb4 have also been extended to human and nonhuman primate HSCs (Buske et al., 2002; Zhang et al., 2006) . As described in more detail in a later section, additional Hox and variant Hox genes have also been shown to be potent stimulators of HSC expansion arguing for their important role in HSC self-renewal. Nevertheless, convincing evidence to ascertain major impacts of Hox on self-renewal or other hematopoietic functions in knockout models has proven somewhat elusive. For Figure 1 Clustered Hox gene organization. The four Hox clusters each contain 8-11 genes and are located on four different chromosomes. Individual genes in different Hox clusters can be aligned into paralogous groups (identical colors) based on the sequence homology within their homeobox regions, and with the homeotic genes of the Drosophila HOM-C cluster. A box above a gene summarizes the important hematopoietic phenotypes exhibited upon engineered overexpression of that Hox gene. Brackets under a gene, or a group of genes, denote mouse knockout models where the role of the indicated gene(s) was assessed in hematopoiesis. BFU-E, erythroid burst-forming unit; CFU-GM, granulocyte/macrophage colony-forming unit; EPs, erythroid progenitors; LL AML, long latency acute myeloid leukemia; MEP, erythroid/megakaryocytic progenitors; MKs, megakaryocytes; MPs, myeloid progenitors; MPD, myeloproliferative disorder.
Hox regulation of hematopoietic and leukemic stem cells B Argiropoulos and RK Humphries example, definitive hematopoiesis was not disrupted in Hoxb4-deficient mice (Brun et al., 2004; Bijl et al., 2006) . These mice did, however, exhibit subtle reductions in HSC and progenitor numbers and a modest impairment of competitive repopulating ability (Brun et al., 2004) . Compound Hoxb3/b4 À/À knockout mice exhibited qualitatively similar but quantitatively more pronounced hematopoietic differences (Bjornsson et al., 2003) . Collectively, these studies indicate that Hoxb3 and Hoxb4 are required, but not necessary, for normal HSC function and that their loss may be compensated for by the self-renewal function of other Hox genes.
In a more recent study, a near-complete Hoxb cluster knockout, Hoxb1-hoxb9
, revealed that the Hoxb cluster is dispensable for normal hematopoiesis as Hoxb1-hoxb9 À/À HSCs as well as wild-type HSCs competed in competitive repopulation assays and retained their full differentiation potential . Gene expression profiling of c-kit þ Hoxb1-Hoxb9 À/À fetal liver cells revealed a downregulation of most Hoxa genes, and upregulation of three Hoxc genes including the Hoxb4 paralog, Hoxc4. The apparent discrepancy in hematopoietic defects reported by Brun et al. (2004) and Bijl et al. (2006) has been explained in the latter study to be the result of the different gene targeting strategies used, a phenomenon for which a precedent exists. Nevertheless, both studies provide strong support for gene redundancy and compensatory mechanisms, as well as cross-regulatory interactions, among Hox genes. These observations warrant further investigation of the role of other Hox paralog 4 genes and the contribution of other Hoxa and Hoxc genes, by way of complete cluster knockouts, in HSC self-renewal.
Like Hoxb4, Hoxa9 is preferentially expressed in primitive hematopoietic cells and downregulated during differentiation, suggesting a key role in early HSC function (Sauvageau et al., 1994; Pineault et al., 2002) . Indeed, Hoxa9-deficient mice exhibited defects in multiple hematopoietic lineages, representing the Hox gene with the most severe hematopoietic phenotypes Izon et al., 1998) . Moreover, competitive repopulation assays revealed that the major defect in Hoxa9 À/À animals was a dramatic impairment of their HSCs to repopulate lethally irradiated recipients after bone marrow transplantation (BMT) (Lawrence et al., 2005) . One plausible explanation for the severity of the Hoxa9 knockout phenotype relative to the mild Hoxb3/b4 À/À or Hoxb4 À/À phenotypes is that Hoxa9 is one of the most highly expressed Hox genes in the HSC compartment, and thus, it could potentially be the major determinant of physiologic HSC self-renewal. This is reinforced by evidence that overexpression of Hoxa9 can enhance HSC regeneration in vivo, albeit with additional impacts on differentiation that ultimately lead to leukemia (Thorsteinsdottir et al., 2002) , thus implicating it in HSC self-renewal.
Additional Hox knockout models where hematopoiesis was assessed include Hoxa5 (Fuller et al., 1999) , Hoxa7 (So et al., 2004) , Hoxa10 (Lawrence et al., 2005) , Hoxb3 (Ko et al., 2007) , Hoxb6 (Shen et al., 1992; Kappen, 2000) and Hoxc8 (Shimamoto et al., 1999) ( Figure 1 ). In summary, their effects range from impaired HSC selfrenewal to impaired myelopoiesis or B lymphopoiesis.
Deficiencies of Hox regulators demonstrate a role for Hox genes in HSC expansion
The MLL (mixed-lineage leukemia) gene is the human homolog of the Drosophila Trithorax gene and is the archetypal member of the Trithorax group of genes that encode chromatin modifiers that are required for the proper maintenance of Hox gene expression during development (Schuettengruber et al., 2007) . Consistent with a major role for Hox genes in hematopoiesis, it has been shown in the murine system that Mll plays an essential and nonredundant role in definitive hematopoiesis by inducing the proliferation and differentiation of hematopoietic progenitors through the maintenance of Hox gene expression, mainly Hox genes from the Hoxb and Hoxc clusters (Ernst et al., 2004) . Indeed, the grossly impaired ability of MLLÀ/À embryonic bodies to form hematopoietic colonies can be rescued by overexpression of Hoxa9, Hoxa10, Hoxb3 or Hoxb4 (Ernst et al., 2004) . Rescue was also observed with the class II homeobox gene cdx4, an upstream regulator of Hox gene expression required for specification of blood progenitors (Davidson et al., 2003; Davidson and Zon, 2006 ) and when overexpressed is sufficient to induce acute myeloid leukemia (AML) alone and in cooperation with the Hox cofactor Meis1 (discussed below) in a murine BMT model (Davidson et al., 2003; Bansal et al., 2006) .
HOX proteins bind target DNA sites in vitro with little obvious selectivity (Hoey and Levine, 1988; Ekker et al., 1994; Mann, 1995) . HOX cofactors of the threeamino acid loop extension class have been shown to interact directly with HOX proteins to increase their DNA-binding affinity and specificity and to modify their transregulatory properties (Moens and Selleri, 2006) . In general, HOX proteins from paralog groups 1-10 interact physically with PBX1, while those from paralog groups 9-13 interact with MEIS1 (Shen et al., 1997) . Thus, loss-of-function mutations of Hox cofactors are predicted to disrupt multiple HOX-dependent pathways. Indeed, Pbx1 and Meis1 mutant animals are embryonic lethal and recapitulate the HSC defects observed in Hox knockout models, indicative of a role for these genes in HSC self-renewal/proliferation (DiMartino et al., 2001; Hisa et al., 2004) .
The unequivocal role of Hox genes in the pathogenesis of acute leukemia A central role for HOX genes in hematological malignancies is supported by the frequently observed elevation of HOX and MEIS1 gene expression in AML patient samples (Golub et al., 1999; Kawagoe et al., 1999; Lawrence et al., 1999; Afonja et al., 2000; Drabkin et al., 2002) . Indeed, HOXA9 is the single most highly correlated gene (out of 6817) for poor prognosis in AML (Golub et al., 1999) . Interestingly, gene expression profiling of AML cells with mutations in the nucleophosmin (NPM1) gene, which represent the most frequent acquired molecular abnormalities in AML, are highly associated with a stem cell molecular signature that includes activation of HOX genes and MEIS1 (Alcalay et al., 2005) .
HOX gene deregulation has also been documented in lymphoid leukemias (Imamura et al., 2002) . Gene expression analysis showed that the whole HOXA gene cluster was dramatically dysregulated in T-cell acute lymphocytic leukemia samples harboring the TCRb-HOXA rearrangement (Speleman et al., 2005; Cauwelier et al., 2007) . HOXA genes were also found to be upregulated in MLL and CALM-AF10-related T-cell acute lymphoblastic leukemias cases, strongly suggesting that HOXA genes are oncogenic in these leukemias (Soulier et al., 2005) .
As described previously, in experimental model systems using retroviral gene transfer into murine BM cells followed by transplantation, we and others have shown that enforced overexpression of select Hox genes, such as Hoxa9, Hoxa10, Hoxb3, Hoxb6 or Hoxb8, confer a growth advantage in vitro and in vivo and leads to long latency leukemia Thorsteinsdottir et al., 1997; Kroon et al., 1998; Fischbach et al., 2005) . The long latency of disease onset suggests that additional genetic perturbations are required for the progression to overt leukemia. Indeed, co-overexpression of Meis1 collaborates with all Hox genes tested thus far, including the non-leukemogenic Hoxb4, to induce rapid onset AML (Kroon et al., 1998; Thorsteinsdottir et al., 2001; Pineault et al., 2004; Fischbach et al., 2005) . These observations strongly indicate that dysregulation of Hox pathways are a dominant mechanism of leukemic transformation.
NUP98-HOX fusion genes HOX genes have been directly linked to leukemia by virtue of their involvement in leukemia-specific translocations. To date, eight clustered Abd-B HOX genes have been found fused to the nucleoporin gene NUP98 in human leukemia (Figure 1 ) and have been identified in patients with AML, post-therapy AML and chronic myeloid leukemia (Slape and Aplan, 2004; Nakamura, 2005) . The novel fusion oncoproteins contain the N-terminal domain of NUP98, which may confer transcriptional activity on the novel fusion through recruitment of the transcriptional coactivators CREB binding protein and p300 (Kasper et al., 1999) or histone deacetylase 1 (Bai et al., 2006) , fused to the C-terminal domain of its HOX partner, which includes the homeodomain. Consistent with a role in modulating transcription, gene expression profiling of NUP98-HOXA9-expressing myeloid cells revealed a significant increase in the number of genes upregulated compared to HoxA9-expressing myeloid cells (Ghannam et al., 2004) . It has also been proposed that the transforming potential of NUP98-HOX fusions may reflect their increased protein stability (Calvo et al., 2002; Chung et al., 2006) or their ability to alter nucleocytoplasmic transport of mRNA and/or protein (Lam and Aplan, 2001 ).
The direct involvement of NUP98-HOX fusion genes in the pathogenesis of AML was demonstrated in the murine BMT model with retroviral overexpression of NUP98-HOXA9 or NUP98-HOXD13, which resulted in a myeloproliferative disease that progressed to AML after a long latency Pineault et al., 2003) . Transgenic knock-in models of NUP98-HOXA9 or NUP98-HOXD13 confirmed these observations (Iwasaki et al., 2005; Lin et al., 2005) . We have reported that the ability of Hox genes to induce leukemia as NUP98 fusion partners is not restricted to the naturally occurring Abd-B Hox genes and that their potency as single agents to induce leukemia differ among Hox genes, indicating differential and common properties of many Hox genes (Pineault et al., 2004 ). Strikingly, all tested NUP98-HOX fusions collaborated with Meis1 to accelerate disease onset Calvo et al., 2002; Pineault et al., 2003) , arguing that these fusions continue to act in Hox-dependent pathways and point to a potent core property of Hox that we propose may lie in their common ability to intensify or reactivate selfrenewal programs.
We have exploited the strong transforming potential of NUP98-HOXD13 and NUP98-HOXA10 to establish transplantable, preleukemic myeloid lines composed of early myeloid progenitors with extensive in vitro selfrenewal capacity, short-term myeloid repopulating activity and low propensity for spontaneous leukemic conversion (Pineault et al., 2005) . These lines appear to recapitulate the pathologic and clinical attributes of human AML and have provided new opportunities to investigate the molecular mechanisms underlying the progression from a preleukemic to leukemic state upon retroviral transduction with Hox collaborators, such as Meis1 and Flt3 (Pineault et al., 2005; Palmqvist et al., 2006) .
MLL fusion genes
Rearrangements involving MLL fusion genes, generated as a consequence of chromosomal translocations fusing N-terminal sequences of MLL to 1 of over 40 functionally diverse group of C-terminal fusion partners (Daser and Rabbitts, 2005) , constitute 5% of all AML cases and 22% of those with acute lymphoblastic leukemia (De Braekeleer et al., 2005) . Gene expression analyses revealed HOX gene dysregulation in all types of MLL fusion-associated T-and B-cell acute lymphoblastic leukemias (Rozovskaia et al., 2001; Armstrong et al., 2002; Yeoh et al., 2002; Ferrando et al., 2003) , implicating HOX genes as integral factors in MLL fusion-associated leukemias. Furthermore, leukemias associated with MLL rearrangements show upregulation of HOXA9 and MEIS1 (Yeoh et al., 2002; Kohlmann et al., 2003; Tsutsumi et al., 2003; Fine et al., 2004) , which, as discussed below, may be a common pathway that unifies diverse initiating events in many myeloid leukemias.
Mice transplanted with BM cells engineered to overexpress various MLL fusion genes develop leukemias, and in the case of the MLL-ENL fusion, expression of Hox genes and Hox cofactors were required for the initiation and maintenance of transformation of myeloid progenitor cells Zeisig et al., 2004; Horton et al., 2005) . Specifically, retroviral transduction of MLL-ENL into wild type or Hoxa9 À/À primary myeloid progenitors revealed the necessity of Hoxa9 in MLL-ENL-mediated leukemogenesis . Moreover, MLL-ENL immortalization of myeloid progenitor cells could be substituted for by overexpression of HoxA9 and Meis1 (Zeisig et al., 2004) , and was dependent on the activity of the oncoprotein c-Myc (Schreiner et al., 2001 ), a downstream effector of Hoxb4 that is sufficient to induce HSC self-renewal (Satoh et al., 2004) . By contrast, analogous studies in a germline mouse model of Mll-AF9-mediated leukemogenesis suggest that Hoxa9 is not necessary for leukemia but does influence the phenotype of the leukemia (Kumar et al., 2004) . Gene expression profiling of Mll-AF9-expressing BM cells revealed overexpression of the Hoxa cluster genes, Hoxa5 to Hoxa9, which the authors propose represents the Mll-AF9-triggered 'Hox code' that defines this oncogene. Redundancy and/or overlapping function(s) among HOX were proposed to account for the loss of Hoxa9. Collectively, these data indicate that MLL fusion genes contribute to pathogenesis of leukemia through dysregulated Hox gene expression.
Meis1 and Flt3 in Hox-mediated leukemia
The proto-oncogene Meis1 was first identified, together with Hoxa7 and Hoxa9, as a common viral integration site in myeloid leukemic cells of BXH-2 mice (Moskow et al., 1995) . We and others have subsequently demonstrated that overexpression of Meis1 collaborates with multiple native and NUP98-HOX fusion genes to accelerate the onset of AML in the murine BMT models (Kroon et al., 1998 Thorsteinsdottir et al., 2001; Pineault et al., 2003 Pineault et al., , 2004 Fischbach et al., 2005) . Curiously, wild-type Meis1 has no transforming activity alone but can be engineered to do so when fused to the potent transactivating domain of VP16 (Mamo et al., 2006; Wang et al., 2006) , thus linking its oncogenicity to transcriptional activation of its downstream target genes. However, collaboration with Hox may be central as suggested by frequent insertional activation of Hoxa genes in the VP16-Meis1 model (Mamo et al., 2006) . The molecular mechanisms responsible for the collaboration of Hox or NUP98-HOX fusions with Meis1 in leukemic transformation are not fully understood. A plausible hypothesis posits that deregulated expression of Hox or NUP98-HOX fusion genes program an increase in self-renewal potential and/or a block in hematopoietic differentiation thus establishing a preleukemic population of BM cells, and deregulated Meis1 expression programs a proliferative and/or survival advantage to these preleukemic cells leading to the emergence of leukemic stem cells (LSCs). This hypothesis is corroborated by the finding that MEIS1 upregulates the pro-proliferative and pro-survival receptor tyrosine kinase Flt3 in Hoxa9 and NUP98-HOX models of leukemia, indicating that Flt3 is a major downstream effector of the leukemic collaboration between Hox and Meis1 (Wang et al., 2005 Palmqvist et al., 2006) . Consistent with this, elevated wild-type FLT3 levels are frequently observed in AML samples and correlate with elevated expression of HOX and MEIS1 (Ozeki et al., 2004; Quentmeier et al., 2004) .
We have recently demonstrated that overexpression of wild-type Flt3 is sufficient to collaborate with NUP98-HOX fusions to induce AML (Palmqvist et al., 2006) . However, disease induced with NUP98-HOX þ Flt3 develops with a longer latency than NUP98-HOX þ Meis1, suggesting that Meis1 triggers additional leukemogenic pathways. This is supported by (1) the identification of other Meis1-regulated genes implicated in stem cell biology, including CD34 (Wang et al., 2005) and c-Myb (Hess et al., 2006) , and (2) by the dispensability of Flt3 in HoxA9 þ Meis1 (Morgado et al., 2007) and NUP98-HOXD13 þ Meis1-mediated leukemogenesis (Argiropoulos and Humphries, submitted). Further identification and characterization of Meis1-regulated genes and the regulatory pathways they control is essential to resolve the molecular mechanisms underlying the potent effect of Meis1 on Hox and NUP98-HOX-mediated leukemogenesis.
HOX as potent stimulators of HSC expansion
The ability of HSCs to provide for the sustained production of all blood lineages is accomplished by a balance between extensive HSC expansion characterized by purely symmetrical self-renewal divisions that occurs during embryogenesis and at times of hematopoietic stress, and the homeostatic maintenance of HSC numbers that likely reflect asymmetrical self-renewal divisions that give rise to one HSC and one committed progenitor cell.
As mentioned previously, it now appears that Hoxb4 is among the most potent stimulators, so far known, of HSC expansion both in vitro and in vivo, likely reflecting its ability to promote symmetrical self-renewal divisions. Engineered retroviral overexpression of Hoxb4 in the mouse BMT model induced a 1000-fold net increase in transduced HSCs within 3-5 months after transplantation versus 20-fold for the control (Sauvageau et al., 1995; Thorsteinsdottir et al., 1999; Antonchuk et al., 2001) . In addition, the rate and magnitude of HSC regeneration was dramatically enhanced in the Hoxb4-transduced animals compared to the control. We subsequently demonstrated that Hoxb4 induced a rapid (12 days) 40-fold ex vivo expansion of HSCs, which reconstituted both myeloid and lymphoid compartments in vivo without inducing leukemia (Antonchuk et al., 2002) . Investigation into the molecular mechanisms underlying Hoxb4-mediated HSC expansion revealed that DNA binding was essential and that physical interaction with the HOX cofactor PBX1 was dispensable (Beslu et al., 2004) . Interestingly, suppression of Pbx1 expression enhanced in vivo Hoxb4-mediated HSC expansion 20-to 50-fold greater than HOXB4 alone (Krosl et al., 2003) . Curiously, PbxÀ/À BM cells show no proliferative advantage. The Hoxb4 (high)-Pbx1 (low) collaboration has recently been extended to ex vivo cultures, achieving a remarkable 100 000-fold expansion in a 2-week time period while preserving their stem cell properties (Cellot et al., 2007) . These data suggest that PBX1 activity negatively modulates the growth-enhancing effects of HOXB4.
Our finding that a subset of NUP98-HOX fusion genes blocked hematopoietic differentiation when retrovirally overexpressed in murine BM (Pineault et al., 2004 (Pineault et al., , 2005 prompted us to test whether these fusions may be used to stimulate HSC expansion. Intriguingly, both engineered NUP98-HOXB4 and NUP98-HOX-A10HD (NUP98 fused only to the homeobox of HOXA10) were extremely potent stimulators of ex vivo HSC expansion with net levels of 300-fold for NUP98-HOXB4 and >2000-fold for NUP98-HOXA10HD demonstrated in 7 days in culture (Ohta et al., 2007) . Like Hoxb4, both fusions reconstituted normally both myeloid and lymphoid compartments in vivo without inducing leukemia. The level of ex vivo HSC expansion obtained for NUP98-HOXA10HD and Hoxb4 (high)-Pbx1 (low) are unprecedented and, according to the reported doubling time of HSCs (Uchida et al., 2003) , are near-maximal symmetrical expansions.
Together, the ability to exploit Hox and NUP98-HOX fusion genes to expand HSCs at near-maximal levels, thus producing a large number of pluripotent and differentiation-competent HSCs, will provide tools to elucidate the molecular mechanisms of HSC self-renewal and will have major clinical implications with respect to BMT therapy. Moreover, as a key function of Hox is their ability to impact on self-renewal, this logically implies that this might underpin their role in leukemia.
HOX and the leukemic stem cell
The field of oncology is undergoing a revolution in considering in which stem cells are seen as the key determinant of the origin and nature of cancer. This concept gained enormous impetus with the early findings in the field of leukemia by Bonnet and Dick (1997) who demonstrated that the cell capable of initiating human AML in the NOD/SCID mouse model is extremely rare, is immunophenotypically similar to normal NOD/SCID-repopulating HSCs and is capable of differentiating (asymmetric division) in vivo into leukemic blast cells. These and more recent findings (Hope et al., 2004) strongly suggest that leukemic cells exist in a hierarchical state in which only a small number of cells are able to self-renew extensively, and thus capable of initiating and maintaining the leukemic clone. This hierarchical model of leukemia in which a rare stem cell initiates and maintains disease has since been extended to a range of other tumors including multiple myeloma (Matsui et al., 2004) , mammary carcinomas (Ponti et al., 2005) , colon cancer (O'Brien et al., 2007) , prostate cancer (Xin et al., 2005) and brain tumors (Singh et al., 2004) . Such findings raise great interest in both the target cells that can give origin to LSCs and the mechanisms underlying their key properties such as self-renewal.
In recent years, investigations into the origin of human LSCs have revealed that these cells are strikingly similar to normal HSCs, with respect to their ability for self-renewal, cell-surface markers and differentiation capacities (Blair et al., 1998; Miyamoto et al., 2000; Hope et al., 2004; Taussig et al., 2005) . Thus, LSCs may be derived from normal HSCs that have acquired an enhanced self-renewal program followed by additional transforming mutations. Alternatively, LSCs may be derived from committed progenitors or lineage-positive cells that have reacquired the ability to self-renew and, subsequently, to proliferate or inhibit apoptosis. In either scenario, there is great interest in elucidating the mechanisms that are responsible for intensifying or reactivating the self-renewal program.
Taking into account the role of Hox genes in HSC self-renewal, we propose that dysregulation of HOX activity may be a central mechanism underlying the self-renewal capacity of LSCs, regardless of origin. Support for this hypothesis comes from multiple murine studies demonstrating that purified committed hematopoietic progenitors, with limited self-renewal capacities, engineered to overexpress the Hox gene regulators MLL-AF9 (Krivtsov et al., 2006) , MLL-ENL (Cozzio et al., 2003) or MLL-GAS7 (So et al., 2004) can be transformed into LSCs. In the latter study, leukemic transformation of committed progenitors by MLL-GAS7 was Hoxa7 or Hoxa9-independent. However, considering the high degree of redundancy in HOX function this most likely remains a Hox-dependent transformation. Furthermore, overexpression of the oncogene MOZ-TIF2, but not BCR-ABL, in committed myeloid progenitors such as the common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs), which have no self-renewing capacity, can induce leukemia in mice by imparting self-renewal potential to these progenitors (Huntly et al., 2004) . We predict that MOZ-TIF2, like the fusion oncoprotein MOZ-CBP (MYST3-CREBBP), establishes a 'Hox code' conducive to extensive self-renewal (Camos et al., 2006) . Indeed, MOZ is a regulator of Hox genes during development (Miller et al., 2004; Crump et al., 2006) . The inability of BCR-ABL to turn on the selfrenewal program in any progenitor cell population suggests that the cellular target of BCR-ABL-mediated leukemogenesis is the normally self-renewing HSC. The HSC as a cellular target for leukemic transformation has also been described for JunB (Passegue et al., 2004) and STAT5-mediated leukemogenesis (Kato et al., 2005) .
More recently, it has been demonstrated that MLL-AF9 leukemia can be initiated in myeloid cells distal to the committed progenitors (Somervaille and Cleary, 2006) . These leukemia-initiating cells were relatively abundant and most likely accumulated additional genetic events through the serial BMTs to become fully competent LSCs. Consistent with the hypothesis that Hox genes drive the self-renewal program in LSCs of any origin, Hoxa gene expression was elevated in these lineage positive LSCs. Similarly, it has been shown that the LSC in murine CALM/AF10-positive AML was positive for the lymphoid associated surface antigen B220, raising the possibility that the LSC in a subset of AMLs is a lymphoid progenitor or a myeloid progenitor with lymphoid characteristics (Deshpande et al., 2006) . Although the level of Hox gene expression was not reported in these lineage-positive LSCs, it would be of interest to determine if their novel ability to self-renew is a result of dysregulation of Hox gene expression, more precisely, genes of the Hoxa cluster. Indeed, CALM/ AF10 is a known upstream regulator of Hoxa gene expression (Dik et al., 2005; Bergeron et al., 2006; Okada et al., 2006) .
It is becoming increasingly obvious that the mechanisms underlying HSC self-renewal control extend beyond the function of Hox. For example, the Polycomb group gene Bmi1 has emerged as a crucial regulator of HSC and LSC self-renewal (Lessard and Sauvageau, 2003; Park et al., 2003; Iwama et al., 2004) . Bmi1 negatively regulates Hox gene expression during development (van der Lugt et al., 1996) , thus it is surprising that its role in self-renewal has not been linked to Hox gene regulation. Rather, Bmi1 controls cellular proliferation by silencing the CDKN2A locus that encodes the cell-cycle inhibitor genes p16
Ink4a and p19 ARF (Jacobs et al., 1999) . Other pathways implicated in HSC self-renewal control include the Wnt (b-catenin) (Reya et al., 2003) , Notch (Varnum-Finney et al., 2000) and Shh (Bhardwaj et al., 2001 ) signaling pathways. Dissection of these pathways and elucidation of their interplay will be of great interest.
Toward a mechanistic understanding of Hox genes
On the basis of our current understanding of the role of Hox genes in normal hematopoiesis and leukemogenesis, we hypothesize that a core function of Hox and NUP98-HOX fusions is the ability to initiate and maintain a state of self-renewal that is necessary but not sufficient for the development of overt leukemia.
A major focus of future research will be to explore the mechanism(s) by which Hox genes initiate and/or intensify self-renewal in normal HSCs or in later progenitors and how this may impact on the origin and function of LSCs. Many avenues of investigation remain open. Chief among these are to identify the cell targets within the hematopoietic hierarchy that can respond to Hox pathways and thus give origin to LSCs. The collaborating genes necessary for frank leukemic transformation in concert with Hox remain to be elucidated fully although much progress in this area is being made (Iwasaki et al., 2005; Jin et al., 2007) . Crucial for further insight will be the delineation of the target genes regulated by Hox of which there is still little known, and identification of the likely protein interactions, extending beyond the known HOX cofactors, that mediate the transcriptional activity of HOX. Elucidation of these issues will undoubtedly shed light into the mechanism of Hox-induced self-renewal and into the mechanisms underlying the emergence of the LSC in leukemia.
